Skip to main content
. 2020 Sep 25;9(10):3093. doi: 10.3390/jcm9103093

Figure 2.

Figure 2

Conjunctival papillae formation in the enteric-coated LF (eLF) with TALYMUS® group compared to that in the placebo group (12-week treatment). Both groups were also treated with 0.1% tacrolimus ophthalmic suspension. Papillae formation in the palpebral conjunctiva was evaluated using the following clinical evaluation criteria for allergic conjunctival diseases: diameter > 0.6 mm (3), diameter 0.3–0.5 mm (2), diameter 0.1–0.2 mm (1), and no manifestation (0). Horizontal bar represents the groups and vertical bar represents the score; papillae formation score changed over the 12-week treatment (Month–0 Month). * p < 0.01, Unpaired T test.